The Global Health Body Sounds Warning Over Severe Scarcity of Obesity Injections

Under a tenth of patients who could benefit from obesity jabs like Wegovy are able to get them, warns the global health agency as it publishes its inaugural advice on the therapies.

Given in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable access to GLP-1 medication.

Per estimates, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.

"The new guidelines affirms that obesity is a chronic disease that can be treated with holistic and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are key obstacles to universal availability to the injections that can help people shift substantial weight, explains the organization.

GLP-1 Therapy Supply Crisis

Even under the present most optimistic outlook, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of the global need, as stated by the WHO.

The guideline calls on nations and manufacturers to increase access, via strategies including patent sharing.

Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is set to lapse in several countries in 2026.

How Weight-Loss Jabs Function

GLP-1 drugs replicate a body's own hormone to reduce digestion speed, suppress the appetite and increase feelings of fullness so users eat less.

People usually see weight reduction after several weeks of beginning the regular doses.

Evidence points to users may regain a significant portion after a year of discontinuing the medication, as their usual appetite come back.

Being above a healthy weight elevates your chance for contracting health problems, like type 2 diabetes, heart disease, stroke, and some cancers.

Excess weight concerns people in every country and was associated with 3.7 million deaths worldwide in 2024, according to the WHO.